NewAmsterdam Pharma Company N.V. (NAMSW) Return on equity 2022–2025
NewAmsterdam Pharma Company N.V. (NAMSW) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-29.8%FY2025 · since FY2022: -5.3% → -29.8%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -29.8% | +2.1 pp |
| FY2024 | -31.9% | +29.5 pp |
| FY2023 | -61.4% | -56.1 pp |
| FY2022 | -5.3% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More NAMSW financial trends
NAMSW RevenueNAMSW Net incomeNAMSW Net marginNAMSW Gross profitNAMSW Gross marginNAMSW Operating incomeNAMSW Operating marginNAMSW Operating cash flowNAMSW Free cash flowNAMSW Capital expendituresNAMSW Stock buybacksNAMSW Dividends paidNAMSW Total assetsNAMSW Total liabilitiesNAMSW Shareholders’ equityNAMSW overview →